tradingkey.logo
tradingkey.logo

enVVeno Medical Corp

NVNO
0.355USD
+0.013+3.74%
終値 12/24, 13:00ET15分遅れの株価
7.17M時価総額
損失額直近12ヶ月PER

enVVeno Medical Corp

0.355
+0.013+3.74%

詳細情報 enVVeno Medical Corp 企業名

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.

enVVeno Medical Corpの企業情報

企業コードNVNO
会社名enVVeno Medical Corp
上場日May 31, 2018
最高経営責任者「CEO」Berman (Robert A)
従業員数37
証券種類Ordinary Share
決算期末May 31
本社所在地70 Doppler
都市IRVINE
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号92618
電話番号19492612900
ウェブサイトhttps://envveno.com/
企業コードNVNO
上場日May 31, 2018
最高経営責任者「CEO」Berman (Robert A)

enVVeno Medical Corpの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
97.44K
--
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
11.15K
+7.73%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Jennifer Bright
Ms. Jennifer Bright
Chief Financial Officer
Chief Financial Officer
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
97.44K
--
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
11.15K
+7.73%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--

収益内訳

会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。

株主

更新時刻: Thu, Dec 4
更新時刻: Thu, Dec 4
株主統計
種類
株主統計
株主統計
比率
Satterfield (Thomas A Jr)
9.02%
Perceptive Advisors LLC
8.70%
Kingdon Capital Management, L.L.C.
6.72%
The Vanguard Group, Inc.
4.26%
CM Management, LLC
2.97%
他の
68.33%
株主統計
株主統計
比率
Satterfield (Thomas A Jr)
9.02%
Perceptive Advisors LLC
8.70%
Kingdon Capital Management, L.L.C.
6.72%
The Vanguard Group, Inc.
4.26%
CM Management, LLC
2.97%
他の
68.33%
種類
株主統計
比率
Individual Investor
10.76%
Investment Advisor
10.13%
Private Equity
8.70%
Hedge Fund
7.28%
Investment Advisor/Hedge Fund
1.91%
Research Firm
1.34%
Venture Capital
0.21%
他の
59.67%

機関投資家保有株

更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
76
5.69M
28.14%
-667.58K
2025Q2
75
3.80M
19.76%
-3.06M
2025Q1
73
3.82M
21.80%
-3.21M
2024Q4
75
4.44M
25.31%
-1.95M
2024Q3
71
5.27M
30.14%
+688.15K
2024Q2
65
3.79M
29.68%
-1.51M
2024Q1
67
4.10M
32.04%
-789.97K
2023Q4
59
4.71M
36.59%
+2.14M
2023Q3
57
2.68M
28.24%
-1.00M
2023Q2
55
2.71M
28.61%
-1.36M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
Perceptive Advisors LLC
1.28M
6.68%
+1.28M
--
Jun 30, 2025
Kingdon Capital Management, L.L.C.
1.36M
7.06%
+500.00K
+58.19%
Sep 02, 2025
The Vanguard Group, Inc.
698.34K
3.63%
+97.43K
+16.21%
Jun 30, 2025
Westside Investment Management, LLC
279.52K
1.45%
+20.48K
+7.90%
Jun 30, 2025
Geode Capital Management, L.L.C.
199.51K
1.04%
+2.21K
+1.12%
Jun 30, 2025
J.P. Morgan Securities LLC
182.30K
0.95%
-11.91K
-6.13%
Jun 30, 2025
詳細を見る

関連ETF

更新時刻: Tue, Dec 2
更新時刻: Tue, Dec 2
銘柄名
比率
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
比率0%
DFA Dimensional US Sustainability Core 1 ETF
比率0%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
種類
比率
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
日付
種類
比率
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1

よくある質問

enVVeno Medical Corpの上位5名の株主は誰ですか?

enVVeno Medical Corpの上位5名の株主は以下のとおりです。
Perceptive Advisors LLCは1.28M株を保有しており、これは全体の6.68%に相当します。
Kingdon Capital Management, L.L.C.は1.36M株を保有しており、これは全体の7.06%に相当します。
The Vanguard Group, Inc.は698.34K株を保有しており、これは全体の3.63%に相当します。
Westside Investment Management, LLCは279.52K株を保有しており、これは全体の1.45%に相当します。
Geode Capital Management, L.L.C.は199.51K株を保有しており、これは全体の1.04%に相当します。

enVVeno Medical Corpの株主タイプ上位3種は何ですか?

enVVeno Medical Corpの株主タイプ上位3種は、
Satterfield (Thomas A Jr)
Perceptive Advisors LLC
Kingdon Capital Management, L.L.C.

enVVeno Medical Corp(NVNO)の株式を保有している機関の数はいくつですか?

2025Q3時点で、enVVeno Medical Corpの株式を保有している機関は76社あり、保有株式の総市場価値は約5.69Mで、全体の28.14%を占めています。2025Q2と比較して、機関の持ち株は8.37%増加しています。

enVVeno Medical Corpの最大の収益源は何ですか?

--において、--部門がenVVeno Medical Corpにとって最大の収益を生み出しており、その金額は--で、全収益の--%を占めています。
KeyAI